Abstract
BackgroundThis study aimed to evaluate the clinical significance of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.MethodsThe clinical data of 133 osteosarcoma patients between January 2011 and February 2018 in our hospital was retrospectively collected and analyzed. NPS was calculated from four parameters, including serum albumin level, serum total cholesterol (TC), lymphocyte-to-monocyte ratio (LMR), and neutrophil-to-lymphocyte ratio (NLR). Patients were divided into three groups (group 1-3) based on NPS. The relationships between NPS and clinical features, overall survival (OS), and progression-free survival (PFS) were analyzed. Two prediction models based on NPS and clinical parameters were developed: clinical parameters model (model A), and the combined model of NPS and clinical parameters (model B). Their predictive performances were further evaluated and compared.ResultsThe median follow-up time of this cohort was 46.0 (range, 5–75) months, while the median OS and PFS was 40 (range, 5–75) months and 36 (range, 5–71) months, respectively. NPS was significantly correlated with gender, tumor location, Enneking stage, pathological fracture, local recurrence, and metastasis (all P < 0.05). Variables of NPS, Enneking stage, local recurrence, metastasis, and NLR were confirmed as independent prognostic factors for OS and PFS by univariate and multivariate Cox analysis. Prediction model B obtained larger AUCs for OS and PFS and showed better consistency between nomogram-predicted and actual survival than that of model A at the follow-up time of 1-, 3-, and 5-year.ConclusionsNPS was a novel, reliable, and multidimensional prognostic scoring system with favorable predictive performance for patients with osteosarcoma.
Highlights
This study aimed to evaluate the clinical significance of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma
Inflammatory diseases refer to a large set of disorders characterized by systemic and organ-specific inflammation, as well as an elevated level of C-reactive protein (CRP), procalcitonin, and erythrocyte sedimentation rate (ESR) [32, 33]. (ii) Patients have history of other malignancies, or they have been previously treated with any anti-cancer agents, non-steroid antiinflammatory drugs (NSAIDs), or antibiotics
Patient characteristics A total of 133 osteosarcoma participants were enrolled in this study according to the inclusion and exclusion criteria
Summary
This study aimed to evaluate the clinical significance of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma. Before the occurrence of multi-disciplinary treatment, the 5-year overall survival (OS) rate was only 10% [2]. Namely surgery plus chemotherapy, targeted therapy, or immunotherapy, the 5-year OS significantly increases to 50–70% [3]. A series of factors have been reported in. Yang et al World Journal of Surgical Oncology (2020) 18:24 one aspect of clinical or pathological characteristics of osteosarcoma patients and might be inherently inaccurate and inadequate for prognostic prediction. Developing a novel, comprehensive, and multidimensional prognostic index composed of assessed and accessible prognostic factors is a possible way to address this problem
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
